Phase 3 PhALLCON study: Ponatinib (PON) versus imatinib (IM) with reduced-intensity chemotherapy (CT) in patients (pts) with newly diagnosed Philadelphia chromosome–positive (Ph+) ALL.
暂无分享,去创建一个
M. Vignetti | H. Kantarjian | G. Martinelli | E. Jabbour | J. Ribera | F. Neumann | D. Gómez-Almaguer | Y. Minami | Jing Xu | Shouryadeep Srivastava